SEC Filings | EyePoint Pharmaceuticals

Form	Description	Filing date	View
EFFECT	EFFECT	Dec 11, 2018	View HTML 9999999995-18-003103.pdf 9999999995-18-003103.rtf
4	Statement of changes in beneficial ownership of securities	Dec 26, 2018	View HTML 0000899243-18-031698.pdf 0000899243-18-031698.rtf
8-K	Report of unscheduled material events or corporate event	Jan 04, 2019	View HTML 0001193125-19-002516.pdf 0001193125-19-002516.rtf 0001193125-19-002516.xls
8-K	Report of unscheduled material events or corporate event	Jan 14, 2019	View HTML 0001193125-19-008307.pdf 0001193125-19-008307.rtf 0001193125-19-008307.xls
8-K	Report of unscheduled material events or corporate event	Jan 18, 2019	View HTML 0001193125-19-012973.pdf 0001193125-19-012973.rtf 0001193125-19-012973.xls
424B5	Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3	Jan 18, 2019	View HTML 0001193125-19-012979.pdf 0001193125-19-012979.rtf 0001193125-19-012979.xls
8-K	Report of unscheduled material events or corporate event	Jan 29, 2019	View HTML 0001193125-19-020750.pdf 0001193125-19-020750.rtf 0001193125-19-020750.xls
3	Initial filing by director officer or owner of more than ten percent.	Jan 29, 2019	View HTML 0001562180-19-000562.pdf 0001562180-19-000562.rtf
4	Statement of changes in beneficial ownership of securities	Jan 29, 2019	View HTML 0001562180-19-000563.pdf 0001562180-19-000563.rtf
5	Annual filing director officer or owner of more than ten percent.	Feb 13, 2019	View HTML 0000899243-19-003415.pdf 0000899243-19-003415.rtf

Data provided by Kaleidoscope.